Roland E Schmieder

Cardiology — Universitätsklinikum Erlangen, Germany

LeadR Profile

Roland E Schmieder Universitätsklinikum Erlangen Germany
4 371 ScienceLeadR Reputation 4371
Network Map

Cardiology

Subspecialties: Nephrology - Endocrinology - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1985 - 2026

Source: PubMed

University of Erlangen-Nuremberg

could not re-read experiences after save", error); return null; } if (persistedEntries === null) { return null; } if (persistedEntries.length === 0 && sent.some((entry) => entry.isvisible !== false)) { console.warn(" re-read after save came back empty, keeping the edited entries"); return null; } this.state.current.experience = persistedEntries; const expected = this.yearsSignature(sent); const received = this.yearsSignature(persistedEntries.map((entry) => ({ isvisible: entry.isvisible, topresent: entry.topresent, year_start: entry.startperiod, year_stop: entry.endperiod }))); if (expected !== received) { console.error(" saved experiences were not persisted as sent", { sent: expected, received: received }); return false; } return true; }, async fetchExperiences() { const response = await $.ajax({ url: ajaxLoadUserData, type: "POST", data: { security: ajaxDataLoadUserData.security, data_to_load: "OrganizationHisto", } }); const parsedData = JSON.parse(response); if (parsedData.loaded === false || !parsedData.user_data || !Array.isArray(parsedData.user_data)) { return null; } return parsedData.user_data.map((value, index) => ({ company: value["name"], url: "", position: (value.hasOwnProperty("position") ? ( value["position"] ) : ( "" ) ), startperiod: value["year_start"], endperiod: value["year_stop"], topresent: (value.hasOwnProperty("topresent") ? ( value["topresent"] ) : ( false ) ), orgid: value["orgid"], isvisible: (value.hasOwnProperty("isvisible") ? ( value["isvisible"] ) : ( true ) ), description: "", tags: [], isOpen: false, ismain: (value.hasOwnProperty("ismain") ? ( value["ismain"] ) : ( (index === 0) ? true : false ) ) })); }, async loadDataOnMount() { this.loading = true; try { const experiences = await this.fetchExperiences(); this.loadFailed = experiences === null; if (experiences !== null) { this.state.current.experience = experiences; } } catch (error) { console.warn(" could not load experiences", error); this.loadFailed = true; } this.loading = false; } }, computed: { experience: { get() { return this.state.current.experience }, }, }, async mounted() { await this.loadDataOnMount() }, } }; })

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1109

Citations

Citations: 97 510 1st author: 156 Last author: 395 Unique author: 45


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Effects of SGLT-2 Inhibitors on Plasma Concentrations and Renal Clearance of the Risk Marker Trimethylamine-N-Oxide in Patients With Type-2 Diabetes.
diabetes mellitus, sodium-glucose transporter 2 inhibitors, mortality, blood, therapeutics, plasma, diabetes mellitus, type 2
Endocrinol Diabetes Metab20260
Treatment with dapagliflozin and empagliflozin reduces concentrations of N4-acetylcytidine in plasma, a biomarker associated with vascular damage.
insulin glargine, 3-hydroxybutyric acid, biomarkers, therapeutics, retinaldehyde, diabetes complications, plasma
Cardiovasc Diabetol20260
The CARDIOLIPID Plan: A Cardiovascular Risk-centred Implementation Framework for the Diagnosis and Management of Dyslipidaemia: Experts' Proposal.
risk management, diagnosis, therapeutics
Eur Cardiol20260
Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial.
kidney diseases, creatinine, body composition, nephrology, body weight, obesity, therapeutics, overweight, cystatins, semaglutide
Clin J Am Soc Nephrol20260
Three-Year Durability of Radiofrequency Renal Denervation: SPYRAL HTN-ON MED.
hypertension, heart diseases, safety, denervation, antihypertensive agents, therapeutics
J Am Heart Assoc20260

Clinical Studies 52

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 8 Study Chair: 1

By phase:

N/A 24
Phase 3 19
Phase 2 4
Phase 4 3
Phase 1 1
Phase 2/Phase 3 1

By status:

Completed 41
Recruiting 5
Active not recruiting 4
Unknown 2

By type:

Interventional 41
Observational 11

By Monocentric/Multicentric:

monocentric 20
multicentric2to4 10
multicentric5to9 1
multicentricup10 21

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
SPYRAL GEMINI Pilot Study
NCT06907147 — diabetes mellitus, kidney diseases, pilot projects, hypertension, pilots, chronic disease, denervation, cardiovascular diseases, disease attributes, multiple chronic conditions, angiography, kidney, vascular diseases, pathologic processes, renal insufficiency, renal insufficiency, chronic
N/ARecruiting2025
Effect of Renal Denervation on Bood Pressure in Patients on Hemodialysis
NCT06556407 — kidney diseases, hypertension, blood, denervation, blood pressure, kidney, therapeutics
N/ARecruiting2024
Proteinuria and Renal Perfusion in Renal Transplant Recipients
NCT06051812 — proteinuria, microcirculation, kidney, kidney failure, chronic, transplants, kidney transplantation, allografts, transplantation
N/AActive not recruiting2021

LeadR Networks

Main global connection map